The Michael J. Fox Foundation

Softeon Bolsters Leadership Team with Notable Supply Chain Experts

Retrieved on: 
Thursday, November 9, 2023

The new team is building on Softeon’s innovative technology and customer-centric culture to create new ways for supply chain leaders to manage constant change within the warehousing industry.

Key Points: 
  • The new team is building on Softeon’s innovative technology and customer-centric culture to create new ways for supply chain leaders to manage constant change within the warehousing industry.
  • “Change management and growth acceleration are on the minds of our customers, as these opportunities also consume the minds of Softeon’s leadership team,” said Hoefflin.
  • As Vice President of Account Management, O'Malley brings over 30 years of experience with multiple industry-leading companies in the supply chain, retail, and payments software and technology space to Softeon.
  • Softeon's new leadership team will be instrumental in advancing Softeon's mission of empowering customers with solutions for managing a constantly changing warehousing industry.

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • This quarter, we have demonstrated proof of technology with our third clinical program, as well as our first proof of mechanism in our UB-312 program for Parkinson’s.
  • Results from the Phase 2a trial of UB-311 in patients with mild AD were published in The Lancet’s eBioMedicine in August 2023.
  • General and administrative expenses were $5.5 million and $7.3 million for the three months ended September 30, 2023, and 2022, respectively.

Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease

Retrieved on: 
Monday, November 6, 2023

The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.

Key Points: 
  • The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.
  • The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France’s National Institute of Health and Medical Research (INSERM).
  • Fox Foundation for Parkinson’s Research (MJFF) to implant the ARC-IM System and investigate the effect of ARC Therapy in six additional participants with Parkinson’s disease.
  • This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson’s disease.

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, November 3, 2023

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.
  • We remain on track to report safety and immunogenicity data from the AD cohort of our ABATE trial of ACI-24.060 this year.
  • Then, in the first half of 2024 results are anticipated from the important Abeta-PET imaging analyses on amyloid plaque reduction following 6 months of treatment.
  • The Company’s cash balance provides sufficient capital resources to progress into Q4 2024 without considering receipt of potential future milestone payments.

Groundbreaking study reveals link between air pollution and incidence of Parkinson’s disease

Retrieved on: 
Tuesday, October 31, 2023

“Regional differences in Parkinson’s disease might reflect regional differences in the composition of the particulate matter.

Key Points: 
  • “Regional differences in Parkinson’s disease might reflect regional differences in the composition of the particulate matter.
  • The population-based geographic study identified nearly 90k people with Parkinson’s disease from a Medicare dataset of nearly 22-million.
  • Those identified with having Parkinson’s disease were geocoded to the neighborhood of residence, enabling researchers to calculate the rates of Parkinson’s disease within each region.
  • Researchers hope the data from this novel study will help enforce stricter policies that will lower air pollution levels and decrease the risk for Parkinson’s disease and other associated illnesses.

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Retrieved on: 
Friday, October 27, 2023

The Nature Communications paper describes the first-in-human trial of ACI-12589 comparing healthy control subjects to patients with a-synucleinopathies and other neurological diagnoses.

Key Points: 
  • The Nature Communications paper describes the first-in-human trial of ACI-12589 comparing healthy control subjects to patients with a-synucleinopathies and other neurological diagnoses.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are proud to have this paper showing the first-ever live images of a-syn in a living human brain published in the prestigious peer-reviewed journal, Nature Communications.
  • As the first imaging agent for a-syn, ACI-12589 represents a major step towards achieving AC Immune’s ambition of developing precision medicine for neurodegenerative diseases.
  • We are encouraged by this first success in MSA and look forward to expanding the potential clinical applications of this tracer, and others emerging from the AC Immune platform.”
    1 For PET imaging, ACI-12589 is radiolabeled with 18F, denoted as [18F]ACI-12589

Tripadvisor Co-Founder Launches New Venture: Give Freely, a Shopping Assistant That Finds Coupons and Donates Sales Commissions to Charities as Consumers Shop

Retrieved on: 
Thursday, October 26, 2023

BOSTON, Oct. 26, 2023 /PRNewswire/ -- Steve Kaufer, the visionary co-founder and longtime leader of Tripadvisor, is excited to announce the launch of Give Freely, a mission-driven company incorporated with the sole purpose of harnessing the collective power of online commerce for charitable good. The company's revolutionary first product is an online shopping assistant that helps people find discounts and donate to the charities of their choice while they shop online. The donations are generated from retailer-paid affiliate marketing sales commissions that other coupon companies pocket as a profit, but Give Freely will divert those funds to charities in desperate need of funding. 100% of every affiliate dollar that comes to Give Freely goes to the user's favorite charity.

Key Points: 
  • The company's revolutionary first product is an online shopping assistant that helps people find discounts and donate to the charities of their choice while they shop online.
  • Consumers can choose which charity they want donations directed to from a pool of over 1.1 million non-profits.
  • "I've always been a believer in the power of large communities taking small, individual actions, and having large collective impacts.
  • With Tripadvisor, that vision led to hundreds of millions of review contributors helping billions of travelers have a better vacation.

Acurex Biosciences to Present at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference

Retrieved on: 
Tuesday, October 10, 2023

Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.

Key Points: 
  • Acurex Biosciences Corporation, a privately-held biopharmaceutical company with a mission to stop neurodegeneration before it starts, has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J.
  • The Parkinson's Disease Therapeutics Conference is the Michael J.
  • Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development.
  • Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from academia and industry, showcasing the most exciting and innovative research from MJFF's research portfolio.

Verily launches Viewpoint Workbench to unify data and accelerate biomedical research

Retrieved on: 
Thursday, October 5, 2023

Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.

Key Points: 
  • Verily, an Alphabet precision health technology company, has launched Viewpoint Workbench, a new enterprise-grade platform to unify multimodal data and accelerate biomedical research.
  • Workbench provides a secure collaborative environment for data generators, research, and biopharma organizations to govern and analyze their data.
  • Data generating organizations, research sponsors, and biomedical researchers can use Workbench to securely connect with stakeholders and partners, explore and analyze multimodal data, and simplify data governance with access control and policy enforcement.
  • Workbench users can tap into a growing ecosystem of data sources and researchers, to build on collective scientific progress, share best practices, and conduct reproducible research.

Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science

Retrieved on: 
Thursday, October 5, 2023

Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.

Key Points: 
  • Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.
  • Nonprofit patient organizations have existed for more than 100 years and now number in excess of 3,000 in the United States.
  • The disease and mission focus of patient organizations has shifted and expanded over time as well.
  • As an example, more than 150 registries are now run by patient organizations, of which 62% focus on rare diseases, positioning patient organizations as custodians of data for their communities.